tbuckley/cabot-search huggingface dataset:
Phase I/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC).
Authors: Afsaneh Barzi, Nilofer Saba Azad, Yan Yang, Denice Tsao-Wei, Rabia Rehman, Marwan Fakih, Syma Iqbal, Anthony B. El-Khoueiry, Joshua Millstein, Priya Jayachandran, Wu Zhang, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2022)

15 Background: Immune check point inhibitors (ICI) are ineffective in MSSCRC. Combination of ICI with targeted agents has the potential to alter the tumor microenvironment and render these tumors vulnerable to ICI. We report the results of the multicenter study of rego and pembro in a diverse patient population with advanced MSSCRC. Methods: This was an investigator-initiated study and enrolled patients (pts) who had failed/were intolerant of chemotherapy at 3 sites. A 3+3 design was used for phase I to evaluate escalating doses of rego (80,120,160, days 1-14/21) in combination with pembro (200m/q3weeks). The primary endpoint was dose limiting toxicities during the first cycle. For phase II, pts received rego at the recommended phase II dose (RP2D) with pembro. The primary endpoint was progression free survival (PFS). Secondary endpoints were overall survival (OS) and objective response rate (ORR). The study was powered to show an improvement in PFS from 1.9 months (CORRECT data) to 2.85 months. Estimated sample size for phase II was 63 pts. Results: Study started in 7/2019 and accrual completed in 7/2021. Of 73 pts, 10 enrolled in phase I and 63 in phase II. RP2D of rego was 80 mg, days 1-14/21, and 70 pts treated at that dose. As of Sep 14, 11 pts remain on treatment. At baseline, median age was 54 years (23-81), 51% female, 53% white, 19% Asian, 12% black, and 11% Hispanic, median prior lines of therapy 2 (1-5), primary tumor location rectosigmoid/rectal 13%, KRAS mutated 68%, BRAF mutated 5%. Liver metastases was present in 78% of the pts. There was no grade 4 toxicity. The most common grade 3 toxicities were rash (20%), followed by hand-foot syndrome and HTN (7%). Dose modification was required in 14%. The most common reason for discontinuation was disease progression (85%), followed by withdrawal of consent (12%). With a median follow up of 5.3 (range:0.6-24.4) months, median PFS was 2.0 (1.8 -3.5) months, and median OS was 10.9 (5.3-NR) months. In 16 pts (23%), with non-liver metastatic disease PFS was 4.3 (1.9-8.4) months. No objective response was observed. Stable disease was observed in 49% of pts, median duration of stable disease was 2 (0.2-18.8) months. Conclusions: This is the largest trial of combination of ICI + rego in MSSCRC reported to date. The trial didn’t meet its primary endpoint, though the median OS is provocative. Analysis of biomarkers for identification of pts with longer duration of benefit is ongoing. Clinical trial information: NCT03657641.
Reply
Authors: Armin Arbab-Zadeh, Julie M. Miller, Carlos E. Rochitte, Marc Dewey, Hiroyuki Niinuma, Ilan Gottlieb, Narinder Paul, Melvin E. Clouse, Edward P. Shapiro, John Hoe, Albert C. Lardo, David E. Bush, Albert de Roos, Christopher Cox, Jeffrey Brinker, Joăo A.C. Lima
Journal: Journal of the American College of Cardiology (2012)
Correction to: Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH
Authors: Na Zhu, Emilia M. Swietlik, Carrie L. Welch, Michael W. Pauciulo, Jacob J. Hagen, Xueya Zhou, Yicheng Guo, Johannes Karten, Divya Pandya, Tobias Tilly, Katie A. Lutz, Jennifer M. Martin, Carmen M. Treacy, Erika B. Rosenzweig, Usha Krishnan, Anna W. Coleman, Claudia Gonzaga-Jauregui, Allan Lawrie, Richard C. Trembath, Martin R. Wilkins, Nicholas W. Morrell, Yufeng Shen, Stefan Gräf, William C. Nichols, Wendy K. Chung
Journal: Genome Medicine (2021)
Instructions for Authors
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Meet members of the GA4GH executive leadership team
Journal: Cell Genomics (2021)

In this interview with Cell Genomics, Ewan Birney, Kathryn North, and Heidi Rehm share their vision for the Global Alliance for Genomics and Health (GA4GH). They discuss how the GA4GH is enabling global data sharing to advance genomics and medicine in ways that will ensure equitable participation and benefit for all populations.
Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Authors: Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Ying-Rui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunhong Hu, Yi-Chun Liu, Yi Jiang, Xia He, Hung-Ming Wang, Wan-Teck Lim, Wangjun Liao, Xiaohui He, Xiaozhong Chen, Zhigang Liu, Xianglin Yuan, Qi Li, Xiaoyan Lin, Shanghua Jing, Yanju Chen, Yin Lu, Ching-Yun Hsieh, Muh-Hwa Yang, Chia-Jui Yen, Jens Samol, Hui Feng, Sheng Yao, Patricia Keegan, Rui-Hua Xu
Journal: Nature Medicine (2022)
Quality and Safety Outcomes of a Hospital Merger Following a Full Integration at a Safety Net Hospital
Authors: Erwin Wang, Sonia Arnold, Simon Jones, Yan Zhang, Frank Volpicelli, Joseph Weisstuch, Leora Horwitz, Bret Rudy
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Hospital consolidations have been shown not to improve quality on average. <h3>Objective</h3> To assess a full-integration approach to hospital mergers based on quality metrics in a safety net hospital acquired by an urban academic health system. <h3>Design, Setting, and Participants</h3> This quality improvement study analyzed outcomes for all nonpsychiatric, nonrehabilitation, non-newborn patients discharged between September 1, 2010, and August 31, 2019, at a US safety net hospital that was acquired by an urban academic health system in January 2016. Interrupted time series and statistical process control analyses were used to assess the main outcomes and measures. Data sources included the hospital's electronic health record, Centers for Medicare &amp; Medicaid Services Hospital Compare, and nursing quality reports. <h3>Exposures</h3> A full-integration approach to the merger that included: (1) early administrative and clinical leadership integration with the academic health system; (2) rapid transition to the academic health system electronic health record; (3) local ownership of quality metrics; (4) system-level goals with real-time actionable analytics through combined dashboards; and (5) implementation of value-based and other analytic-driven interventions. <h3>Main Outcomes and Measures</h3> The primary outcome was in-hospital mortality. Secondary outcomes included 30-day readmission, patient experience, and hospital-acquired conditions. <h3>Results</h3> The 122 348 patients in the premerger (September 2010 through August 2016) and the 58 904 patients in the postmerger (September 2016 through August 2019) periods had a mean (SD) age of 55.5 (22.0) years; the total sample of 181 252 patients included 112 191 women (61.9%), the payor mix was majority governmental (144 375 patients [79.7%]), and most admissions were emergent (121 469 patients [67.0%]). There was a 0.71% (95% CI, 0.57%-0.86%) absolute (27% relative) reduction in the crude mortality rate and 0.95% (95% CI, 0.83%-1.12%) absolute (33% relative) in the adjusted rate by the end of the 3-year intervention period. There was no significant improvement in readmission rates after accounting for baseline trends. There were fewer central line infections per 1000 catheter days, fewer catheter-associated urinary tract infections per 1000 discharges, and a higher likelihood of patients recommending the hospital or ranking it 9 or 10. <h3>Conclusions and Relevance</h3> In this quality improvement study, a hospital merger with a full-integration approach to consolidation was found to be associated with improvement in quality outcomes.
Twentieth Congress of the International Society of Hematology
Journal: JNCI Journal of the National Cancer Institute (1984)

Twentieth Congress of the International Society of Hematology JNCI: Journal of the National Cancer Institute, Volume 72, Issue 2, February 1984, Page 501, https://doi.org/10.1093/jnci/72.2.501-b Published: 01 February 1984
Are enhanced dual chamber detection algorithm superior to single chamber algorithm first results of the multicenter DETECT study Katrin Ziegenbalg, Burkhard H�gl, Nico Doll, Angelika Bucco, Mathias Benthin, Petra Schirdewan, Hans Kottkamp, Gerhard Hindricks, Rainer Hambrecht, Gerhard Schuler. Heart Center Leipzig, Leipzig, Germany
Journal: Journal of the American College of Cardiology (2001)
Initial US multicenter clinical experience: Acute evaluation of atrial autocapture (AAC) capability using affinityS DR device Michael B. Chisner, Roger A. Freedman, Seth Worley, Eric Pena, David Fitzgerald, Grant Simons, David Pederson, Nazam Habnab, Mark Kremers, James L. Duncan, Sandy Malys, Xiaozheng Zhang, and Study Investigators. St. Joseph's Hospital, Savannah, GA, University of Utah &amp; VAMC, Salt Lake City, UT
Journal: Journal of the American College of Cardiology (2001)
Correction to: COVID-19 increased the risk of ICU-acquired bloodstream infections: a case–cohort study from the multicentric OUTCOMEREA network
Authors: Niccolò Buetti, Stéphane Ruckly, Etienne de Montmollin, Jean Reignier, Nicolas Terzi, Yves Cohen, Shidasp Siami, Claire Dupuis, Jean-François Timsit
Journal: Intensive Care Medicine (2021)

A correction to this paper has been published: https://doi.org/10.1007/s00134-021-06379-1
Consolidating Radiotherapy with Immunotherapy
Authors: Maria E. Rodriguez-Ruiz, Miguel F. Sanmamed, Irantzu Serrano-Mendioroz, Ignacio Melero
Journal: Clinical Cancer Research (2021)

Abstract Radiotherapy and immunotherapy can be concomitantly or sequentially combined seeking synergistic effects in terms of control of irradiated tumors and abscopal effects on nonirradiated lesions. Clinical-trial testing of such combinations faces several obstacles to demonstrate efficacy and needs improvements in trial design, patient selection, evaluation of results and biomarker discovery. See related article by Foster et al., p. 5510
An open-label, multicenter, randomized controlled study of mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment in metastatic colorectal cancer: A single-center report.
Authors: Yongkun SUN, Wen Zhang, Zhichao Jiang, Wei Wang, Wang Qu, Ai-Ping Zhou
Journal: Journal of Clinical Oncology (2022)

52 Background: The first-line treatments in metastatic colorectal cancer were FOLFOX, CAPOX, FOLFIRI and even FOLFOXIRI as basic chemotherapy regimen combined with targeted therapy. XELIRI regimen was not recommended because of the concerns about the toxicity, efficacy and controversy in optimal dosage. An increasing number of studies indicated promising efficacy with manageable safety profile of dosage and administration-adjusted XELIRI regimen. Therefore, the present study investigated the efficacy, safety and appropriate dosage of mXELIRI regimen in the first-line treatment of advanced colorectal cancer. Methods: The EXIST study was a multicenter, randomized controlled, non-inferiority study and we performed stratification based on the tumor location (left or right side). In the mXELIRI+Bev group, patients received intravenous infusion of irinotecan (a reduced dosage,150mg/m 2 ) with bevacizumab (5mg/kg) on day 1 and oral administration of capecitabine (2000mg/m 2 /day) tablet on day 1-10/Q14 days. Patients in FOLFIRI+Bev group received intravenous infusion of irinotecan (180mg/m 2 ), calcium folinate (400mg/m 2 ) and 5-Fu (400mg/m 2 ) bolus with bevacizumab (5mg/kg) on day 1 followed by a 46-hour continuous infusion of 5-Fu (2400mg/m 2 )/Q14 days. The primary endpoint was progression-free survival rate at 12 month(PFSR 12m ) and the secondary endpoints included ORR,OS and safety. Results: 142 patients were enrolled and randomly assigned to receive mXELIRI+Bev (n=76) or FOLIRI+Bev (n=66) in our center between May 2018 and April 2021. Baseline characteristics were well balanced between two groups. In the mXELIRI+Bev group, 70 patients were evaluable with an ORR of 60.0% (1 complete response, CR; 41 partial response, PR; 24 stable disease, SD; 4 progression disease PD). While 57 patients were evaluable in the FOLFIRI+Bev group, with an ORR of 63.2% (36 PR; 15 SD; 6 PD). The PFSR 12m for two groups were 32.3% and 21.3%, the median PFS were 9.72 months and 8.77 months, respectively. For safety profiles, no statistical differences were observed in adverse events, such as nausea, vomiting, diarrhea, bone marrow suppression and abnormal liver function. While 10 serious adverse events were recorded in the mXELIRI+Bev group, including intestinal obstruction occurred in 8 patients, intestinal perforation occurred in 1 patients and venous thrombosis occurred in 1 patient. In the FOLIRI+Bev group, intestinal obstruction, venous thrombosis and pulmonary thrombosis was reported in one patient respectively. Conclusions: The modified biweekly XELIRI plus bevacizumab regimen demonstrated promising effect and could be well tolerated based on the data from a single center. Clinical trial information: NCT04247984.
Is the long term outcome of multivessel PTCA in diabetic patient inferior to that of non diabetic patient? 5 year follow-up in the multivessel PTCA multicenter study Katsuya Kitano, Tohru Kobayashi, Hideo Tamai, Takahiko Suzuki, Hideo Nishikawa, Osamu Katoh, MRT investigators. Kyoto Katsura Hospital Cardiovascular Center, Kyoto, Japan
Journal: Journal of the American College of Cardiology (2001)
PLoS Medicine Issue Image | Vol. 4(10) October 2007
Journal: PLoS Medicine (2007)

"In my hands are three ounces of rice," says Kris Litman, who took this photo (see http://www.flickr.com/photos/krislitman/493626935/). "The average person living in chronic hunger receives only this amount of food...daily." We chose the image to highlight this month's special collection of articles exploring the link between poverty, health, and human development. Hunger is a recurring theme of the collection. A research article (Weiser et al. e260) reports an association between food insufficiency and high-risk sexual behavior in women in Botswana and Swaziland. And in this month's debate (Yamey et al. e303), in which we asked 30 people worldwide the question, '"Which single intervention would do the most to improve the health of those living on less than $1 a day?", several interviewees answered "hunger alleviation." Image Credit: "Give us this day.." by Mr. Kris at Flickr.com
Clinical Images: Giant cell arteritis with positive temporal artery biopsy findings but without ultrasound halo sign
Authors: Takeshi Suzuki, Sumiyo Ando, Miho Ohshima, Akitake Suzuki
Journal: Arthritis & Rheumatology (2022)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
JAMA Reader's Choice: Continuing Medical Education
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reduction of ischemia-reperfusion injury in the rat in vivo by DF1681A, an inhibitor of interleukin-8 Laura Calvillo, Riccardo Bertini, Stefano Porzio, Stefano Chimenti, Serge Masson, Francesco Colotta, Roberto Latini. Istituto di Richerche Farmacologiche Mario Negri, Milan, Italy, Dompe' Research Center, L'Aquila, Italy
Journal: Journal of the American College of Cardiology (2001)
Long survival in advanced breast cancer
Authors: M. L. Fuerst
Journal: JAMA (1983)

Adjuvant polychemotherapy can turn the mortality tables more in favor of advanced breast cancer patients, according to reports presented at a recent symposium on innovative cancer chemotherapy held in New York City. Intensive, aggressive, postsurgical polychemotherapy, including prednisone for hormonal catabolic support, can provide a "guarantee" of an extra 2 1/2 years of life for an estimated 200,000 American women who are presently undergoing therapy for recurrent or advanced breast cancer, said Ezra M. Greenspan, MD, associate chief, Division of Medical Oncology, Mount Sinai School of Medicine, New York. Most multi-institution studies of high-risk patients with metastatic breast cancer indicate that five-year survival rarely exceeds 10% to 15%, he told the symposium. Greenspan said, "For the high-risk patient with life-threatening [disease], there is now no question of the need for aggressive polychemotherapy." Greenspan's statements were reinforced by data presented by Richard G. Cooper, MD, chief of oncology at Buffalo (NY)
Common idiopathic pulmonary fibrosis risk variants are associated with hypersensitivity pneumonitis
Authors: Haruhiko Furusawa, Anna L Peljto, Avram D Walts, Jonathan Cardwell, Philip L Molyneaux, Joyce S Lee, Evans R Fernández Pérez, Paul J Wolters, Ivana V Yang, David A Schwartz
Journal: Thorax (2022)

A subset of patients with hypersensitivity pneumonitis (HP) develop lung fibrosis that is clinically similar to idiopathic pulmonary fibrosis (IPF). To address the aetiological determinants of fibrotic HP, we investigated whether the common IPF genetic risk variants were also relevant in study subjects with fibrotic HP. Our findings indicate that common genetic variants in TERC , DSP , MUC5B and IVD were significantly associated with fibrotic HP. These findings provide support for a shared etiology and pathogenesis between fibrotic HP and IPF.
The physician and family planning
Authors: H. I. Lief
Journal: JAMA (1966)

What are the responsibilities of the physician in family planning? Until the last two or three years, most doctors thought little about the matter, assuming that this was not their concern, though they may have been vaguely troubled by the increasing number of reports pointing out the serious consequences of overpopulation. Even if they read that the world's population was going to double by the year 2000, and that in some countries the rate was even higher than this, or that a serious food shortage was even now the result of the population explosion, the average physician was not personally concerned. Numbers are too abstract; it is difficult to visualize a world in which every person will exist on one square foot of space. That kind of visual image is too far from our own experience to be comprehended and, as a result, it becomes an absurdity, without real psychological
Management of Complicated Hepatic Hydatid Cysts
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Device Therapy of Hypertension
Authors: Felix Mahfoud, Markus P. Schlaich, Melvin D. Lobo
Journal: Circulation Research (2021)

In the past decade, efforts to improve blood pressure control have looked beyond conventional approaches of lifestyle modification and drug therapy to embrace interventional therapies. Based upon animal and human studies clearly demonstrating a key role for the sympathetic nervous system in the etiology of hypertension, the newer technologies that have emerged are predominantly aimed at neuromodulation of peripheral nervous system targets. These include renal denervation, baroreflex activation therapy, endovascular baroreflex amplification therapy, carotid body ablation, and pacemaker-mediated programmable hypertension control. Of these, renal denervation is the most mature, and with a recent series of proof-of-concept trials demonstrating the safety and efficacy of radiofrequency and more recently ultrasound-based renal denervation, this technology is poised to become available as a viable treatment option for hypertension in the foreseeable future. With regard to baroreflex activation therapy, endovascular baroreflex amplification, carotid body ablation, and programmable hypertension control, these are developing technologies for which more human data are required. Importantly, central nervous system control of the circulation remains a poorly understood yet vital component of the hypertension pathway and mandates further investigation. Technology to improve blood pressure control through deep brain stimulation of key cardiovascular control territories is, therefore, of interest. Furthermore, alternative nonsympathomodulatory intervention targeting the hemodynamics of the circulation may also be worth exploring for patients in whom sympathetic drive is less relevant to hypertension perpetuation. Herein, we review the aforementioned technologies with an emphasis on the preclinical data that underpin their rationale and the human evidence that supports their use.